Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 29300-381

7 FDA label images from Unichem Pharmaceuticals (usa), Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 29300-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 01)

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 01)
Chemical structure of divalproex sodium, showing the sodium salt of valproic acid and valproic acid molecules forming a coordination complex.*
FDA Label Image

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 02)

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 02)
This chart compares the percent reduction in CPS rate against the percent of patients for Divalproex Sodium Delayed-Release Tablets versus placebo. The vertical axis shows improvement or worsening in CPS rate, with higher values indicating improvement. The horizontal axis shows the percentage of patients. The solid line represents Divalproex Sodium tablets, and the dashed line represents placebo, illustrating greater improvement with the active treatment.*
FDA Label Image

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 03)

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 03)
A chart comparing the percentage reduction in CPS rate among patients treated with high dose versus low dose divalproex sodium delayed-release tablets. The x-axis represents the percentage of patients from 0 to 100, and the y-axis shows the percentage reduction in CPS rate ranging from -100% to 100%, with improvement above zero and worsening below zero. Two lines display patient response trends for each dosing group.*
FDA Label Image

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 04)

Image (5061f4f1 32fe 4ab4 8787 E054053108d0 04)
A bar chart comparing the effects of placebo and divalproex sodium extended-release tablets. The y-axis shows a numerical scale from 0 to 1.2, with the placebo bar reaching 0.6 and the divalproex sodium bar reaching 1.2, marked with an asterisk indicating statistical significance (p=0.006).*
FDA Label Image

Logo (5061f4f1 32fe 4ab4 8787 E054053108d0 05)

FDA Label Image

Divalproex Sodium Extended-release Tablets Usp, 250 mg (100T)

Divalproex Sodium Extended-release Tablets Usp, 250 mg (100T)
Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg, film-coated, extended-release oral tablets. The label indicates once-daily dosing and contains 100 tablets. Manufactured by Unichem Laboratories Ltd. and labeled by Unichem Pharmaceuticals (USA), Inc. Includes storage instructions, a barcode, and medication handling warnings.*
FDA Label Image

Divalproex Sodium Extended-release Tablets Usp, 500 mg (100T)

Divalproex Sodium Extended-release Tablets Usp, 500 mg (100T)
Label for Divalproex Sodium Extended-Release Tablets, USP, 500 mg strength. The label indicates once-daily dosing and includes a quantity of 100 tablets. It mentions valproic acid activity and directions for pharmacists to dispense a medication guide. The product is manufactured by Unichem Laboratories Ltd. in India and labeled by Unichem Pharmaceuticals (USA) Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.